Skip to content
- Analysis of 3297 individuals suggests that the pathogenic germline 5'-UTR variant BRCA1 c.-107A?>?T is not common in south-east Germany.
- Laner A, Benet-Pages A, Neitzel B, Holinski-Feder E
- Fam Cancer. 2020 Mar 21. doi: 10.1007/s10689-020-00175-4. [Epub ahead of print]
- Factors shaping at-risk individuals' decisions to undergo genetic testing for cancer in Asia.
- Sun S, Li ST, Ngeow J.
- Health Soc Care Community. 2020 Mar 20. doi: 10.1111/hsc.12981. [Epub ahead of print]
- Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA.
- Grellety T, Peyraud F, Sevenet N, Tredan O, Dohollou N, Barouk-Simonet E, Kind M, Longy M, Blay JY, Italiano A.
- Ann Oncol. 2020 Mar 17. pii: S0923-7534(20)36362-6. doi: 10.1016/j.annonc.2020.03.283. [Epub ahead of print]
- The Provision of Genetic Testing and Related Services in Quebec, Canada.
- Unim B, De Vito C, Hagan J, Villari P, Knoppers BM, Zawati M.
- Front Genet. 2020 Mar 4;11:127. doi: 10.3389/fgene.2020.00127. eCollection 2020.
- Young Women With Breast Cancer: Treatment, Care, and Nursing Implications.
- Corey B, Smania MA, Spotts H, Andersen M.
- Clin J Oncol Nurs. 2020 Apr 1;24(2):139-147. doi: 10.1188/20.CJON.139-147.
- Acquired multiple secondary BRCA2 mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a BRCA2 germline mutation.
- Tao H, Liu S, Huang D, Han X, Wu X, Shao YW, Hu Y.
- Am J Transl Res. 2020 Feb 15;12(2):612-617. eCollection 2020.
- Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
- Gaba F, Manchanda R.
- Best Pract Res Clin Obstet Gynaecol. 2020 Feb 4. pii: S1521-6934(20)30018-3. doi: 10.1016/j.bpobgyn.2020.01.006. [Epub ahead of print]